Regeneron Beats Wall Street Estimates on Strong Dupixent and Libtayo Sales

Regeneron Pharmaceuticals exceeds Q3 2025 expectations with $3.75B revenue, driven by blockbuster eczema drug Dupixent and cancer treatment Libtayo, despite Eylea competition challenges.